Stockscreener 앱 받기
58.50
4.04%
2.27
시간 외 거래:
58.50
전일 마감가:
$56.23
열려 있는:
$57
하루 거래량:
613.64K
Relative Volume:
1.41
시가총액:
$3.60B
수익:
$101.78M
순이익/손실:
$-259.43M
주가수익비율:
-17.84
EPS:
-3.28
순현금흐름:
$-163.06M
1주 성능:
-10.80%
1개월 성능:
+15.04%
6개월 성능:
+54.11%
1년 성능:
+72.97%
1일 변동 폭
$55.37
$58.64
1주일 범위
$55.37
$66.10
52주 변동 폭
$31.52
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RYTM | 58.50 | 3.60B | 101.78M | -259.43M | -163.06M | -3.28 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Announces Five Presentations at ESPE - GlobeNewswire
Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan
Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com
Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals EVP sells $4.43m in stock - Investing.com
Rhythm Pharmaceuticals Announces Publication of Results - GlobeNewswire
Rhythm Pharma's Obesity Drug Shows 83% Success in Phase 3 Trial, FDA Priority Review Set | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire
Rhythm Pharmaceuticals Awards 15,750 RSUs to New Employees in Talent Acquisition Push | RYTM Stock News - StockTitan
PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals - GuruFocus.com
Goldman Sachs Group Inc Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus.com
High Growth Tech Stocks Featuring Three Prominent US Companies - Simply Wall St
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 52-Week HighWhat's Next? - MarketBeat
HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock By Investing.com - Investing.com Australia
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 4,688 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $69.00 - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance UK
8,594 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Creative Planning - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highligh - GuruFocus.com
Earnings call: Rhythm Pharmaceuticals has reported a successful third quarter in 2024 - Investing.com India
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $64.00 at Needham & Company LLC - MarketBeat
Rhythm Pharmaceuticals CEO to Present at Major Healthcare Investor Conferences | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year HighTime to Buy? - MarketBeat
Rhythm Pharma stock soars to all-time high of $55.65 By Investing.com - Investing.com Canada
Rhythm Pharma stock soars to all-time high of $55.65 - Investing.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 7.4% HigherTime to Buy? - MarketBeat
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 - The Manila Times
What's Next: Rhythm Pharmaceuticals's Earnings Preview - Benzinga
(RYTM) Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Nisa Investment Advisors LLC Has $3.47 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):